Amino Acid, Peptide, or Protein
Novo Nordisk Foundation Commits Over $850M to Danish Life Science Incubator BII Over Next Decade
Novo Nordisk Foundation; BII; life science incubator; $850M; biotech startups; Denmark
JPM26 Day 3: Sanofi CEO on RSV Scrutiny and Regeneron Dupixent Defense
JPM26; Sanofi; RSV; Beyfortus; Paul Hudson; FDA; vaccines; Dupixent; Regeneron
Caldera Therapeutics Launches with $112.5M Funding for China-Licensed IBD Bispecific Antibody
Caldera Therapeutics; IBD; bispecific antibody; $112.5M funding; Qyuns Therapeutics; CLD-423
FDA Requests Eli Lilly and Novo Nordisk to Remove Suicide Warnings from GLP-1 Drug Labels
FDA; GLP-1; suicide warnings; Eli Lilly; Novo Nordisk; Wegovy; Zepbound; Saxenda
Novo Nordisk Refocuses on Diabetes and Obesity to Expand GLP-1 Market at JPM26
Novo Nordisk; diabetes; obesity; GLP-1; JPM26; Mike Doustdar; Wegovy pill; semaglutide
JPM26: Novo Nordisk and Eli Lilly Compete Fiercely in Oral Obesity Treatments
Novo Nordisk; Eli Lilly; oral obesity drugs; JPM26; JPMHC; orglipron; semaglutide
Merck Raises Long-Term Revenue Outlook to $70 Billion by Mid-2030s
Merck; revenue target; $70 billion; mid-2030s; Keytruda; new growth drivers
FDA Requests Flu Vaccine Label Updates for Febrile Seizure Risk in Young Children
FDA; flu vaccine; febrile seizures; label update; children; influenza vaccine
Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting Durable Complete Response and 66.7% ORR in Advanced GC/GEJ
Immunofoco; IMC002; ASCO GI 2026; CAR-T; CLDN18.2; gastric cancer; complete response; ORR
AbbVie Pays $650M Upfront to RemeGen for PD-1/VEGF Bispecific RC148 Rights Outside China
AbbVie; RemeGen; RC148; PD-1/VEGF; bispecific antibody; oncology; licensing deal; $650M; $5.6B